Atara Biotherapeutics (NASDAQ: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, has closed an underwritten public offering of 5,102,041 shares of its common stock at the public offering price of $24.50 per share. According to the update, pre-funded warrants of 2,040,816 shares of its common stock were also sold at a purchase price of $24.4999 per pre-funded warrant share to certain investors. This represents the per share public offering price for the common stock, minus the $0.0001 per share exercise price of each such pre-funded warrant share. Atara Biotherapeutics secured approximately $175.0 million in gross proceeds. In addition, Atara Biotherapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,071,428 shares of its common stock at the public offering price. Roth Capital Partners (“ROTH”) acted as co-manager for the offering.
To view the full press release, visit https://ibn.fm/OyPgQ
About Atara Biotherapeutics Inc.
Atara Biotherapeutics is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases. For more information, please visit www.AtaraBio.com.
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork.